These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 24976388

  • 1. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
    Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD.
    Br J Haematol; 2014 Nov; 167(3):423-6. PubMed ID: 24976388
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 3. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E, Agapidou A, Spanos G, Klonizakis P, Vetsiou E, Mavroudi M, Boura P.
    Hemoglobin; 2015 Feb; 39(5):299-304. PubMed ID: 26177199
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R.
    Ann N Y Acad Sci; 2005 Feb; 1054():183-5. PubMed ID: 16339664
    [Abstract] [Full Text] [Related]

  • 5. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
    Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD.
    Am J Hematol; 2010 Oct; 85(10):818-9. PubMed ID: 20799360
    [Abstract] [Full Text] [Related]

  • 6. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Oct; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 7. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Oct; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 8. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 9. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Sep; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 11. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
    Origa R, Danjou F, Cossa S, Matta G, Bina P, Dessì C, Defraia E, Foschini ML, Leoni G, Morittu M, Galanello R.
    Br J Haematol; 2013 Nov; 163(3):400-3. PubMed ID: 24033185
    [Abstract] [Full Text] [Related]

  • 12. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
    Peng CT, Chang JS, Wang LY, Chiou SS, Hsiao CC, Wang SC, Hung GY, Wu KH.
    Hemoglobin; 2009 Nov; 33(5):304-11. PubMed ID: 19814676
    [Abstract] [Full Text] [Related]

  • 13. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C, Roccabruna E, D'Ascola DG.
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [Abstract] [Full Text] [Related]

  • 14. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC.
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract] [Full Text] [Related]

  • 15. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 16. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V, Berdousi H, Gotsis E, Kattamis A.
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [Abstract] [Full Text] [Related]

  • 17. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
    Ruffo GB, Borsellino Z, Cuccia L, Marocco MR, Gagliardotto F, Tarantino R.
    Clin Drug Investig; 2010 Dec; 30(4):267-73. PubMed ID: 20225910
    [Abstract] [Full Text] [Related]

  • 18. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
    Ktena YP, Athanasiadou A, Lambrou G, Adamaki M, Moschovi M.
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
    [Abstract] [Full Text] [Related]

  • 19. Deferasirox and children: From clinical trials to the real world.
    Origa R, Zappu A, Foschini ML, Leoni G, Morittu M, Moi P, Corpino M, Dessì C.
    Am J Hematol; 2016 Jun; 91(6):E304-5. PubMed ID: 26950047
    [No Abstract] [Full Text] [Related]

  • 20. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
    Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL.
    Br J Haematol; 2015 Mar; 168(6):882-90. PubMed ID: 25402221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.